Agios Pharmaceuticals Receives Overweight Rating from Cantor Fitzgerald

Investment analysts at Cantor Fitzgerald have reaffirmed their "overweight" rating for Agios Pharmaceuticals (NASDAQ:AGIO) in a research note released to investors on Wednesday. This decision reflects the firm’s optimistic outlook for the company’s stock performance.

Recent activity among other analysts also suggests a positive trend for Agios Pharmaceuticals. For example, Royal Bank of Canada raised its price target on the stock from $55.00 to $57.00 and maintained an "outperform" rating in a report dated December 10. Similarly, Scotiabank increased its target price for Agios from $53.00 to $75.00, assigning a "sector outperform" rating in a note on December 9.

Additionally, StockNews.com upgraded Agios Pharmaceuticals from a "sell" rating to a "hold" in a report published on November 9. Furthermore, Raymond James reiterated their "outperform" stance on the stock while setting a price target of $51.00 on October 10. In contrast, Leerink Partners downgraded Agios from